A new treatment to degrade androgen receptors in advanced prostate cancer
Official title: A novel AR degrader in castrate-resistant prostate cancer
Funded at Wayne State University · NIH-10907660 · Data updated 2026-11-12
This study is exploring a new way to help men with castrate-resistant prostate cancer by using special molecules that can remove the proteins that help the cancer grow, aiming to make existing treatments work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wayne State University NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project start | August 15, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $571,810 |
| NIH project number | 5R01CA282040-02 |
| Project ID | NIH-10907660 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with castrate-resistant prostate cancer who have not responded to standard anti-androgen therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet developed resistance to androgen deprivation therapy may not benefit from this research.
What this research studies
This research focuses on developing a novel therapeutic approach to treat castrate-resistant prostate cancer (CRPC) by targeting and degrading androgen receptors (AR) that contribute to cancer progression. The study utilizes innovative molecules called AUTOTACs, which link AR inhibitors to a system that promotes the degradation of AR proteins through autophagy. By effectively removing these receptors, the goal is to overcome resistance to current anti-androgen therapies and improve treatment outcomes for patients with CRPC.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that effectively targets and degrades androgen receptors, potentially improving survival and quality of life for patients with advanced prostate cancer.
How similar studies have gone: While the approach of targeting androgen receptor degradation is innovative, similar strategies in other cancers have shown promise, indicating potential for success in this area.
Where this research is happening
-
Wayne State University
Detroit, United States Active
Researchers
- Principal investigator: Kim, Hyeong-Reh Choi — Wayne State University
- Study coordinator: Kim, Hyeong-Reh Choi
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.